Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix.
Human glioma cells (T98G and A172 cell lines) were cultured on various extracellular matrix (ECM) components including type I, IV and V collagens, fibronectin, laminin, and reconstituted basement membrane (Matrigel), and the role of matrix metalloproteinases (MMPs) in their growth and invasion was examined. T98G glioma cells grew well on these ECM components and invaded the reconstituted basement membrane. In contrast, A172 glioma cells showed growth inhibition on collagen types IV and V and Matrigel without invasion of the Matrigel. Gelatin zymography and enzyme immunoassays demonstrated that T98G glioma cells, but not A172 cells, secrete a large amount of matrix metalloproteinase-2 (MMP-2, 72 kD gelatinase/type IV collagenase = gelatinase A), and this was confirmed by immunoblotting and immunohistochemistry. Of the two different tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), T98G cells produced only TIMP-1 during culture on Matrigel, whereas A172 cells secreted both. Although both human recombinant TIMP-1 and TIMP-2 stimulated T98G cell growth slightly on Matrigel, the in vitro invasiveness was significantly reduced by only recombinant TIMP-2. These results suggest that MMP-2 plays an important role in the ECM invasion of T98G human glioma cells in vitro.
Nakagawa
T
T
Department of Neurosurgery, Fukui Medical School, Japan.
Kubota
T
T
Kabuto
M
M
Fujimoto
N
N
Okada
Y
Y
D001932:Brain Neoplasms; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000502:physiology; D003094:Collagen; D017364:Collagenases / Q000378:metabolism / Q000502:physiology; D004338:Drug Combinations; D005109:Extracellular Matrix / Q000473:pathology; D018093:Gelatinases / Q000378:metabolism* / Q000502:physiology; D005910:Glioma; D006023:Glycoproteins / Q000378:metabolism / Q000502:physiology; D006801:Humans; D007797:Laminin; D020781:Matrix Metalloproteinase 1; D020778:Matrix Metalloproteinase 2; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism / Q000502:physiology; D020780:Matrix Metalloproteinase 9; D008666:Metalloendopeptidases / Q000378:metabolism* / Q000502:physiology; D009361:Neoplasm Invasiveness / Q000473:pathology; D009363:Neoplasm Proteins / Q000378:metabolism / Q000502:physiology; D011480:Protease Inhibitors / Q000378:metabolism; D011506:Proteins / Q000378:metabolism / Q000502:physiology; D011509:Proteoglycans; D019716:Tissue Inhibitor of Metalloproteinase-2; D019714:Tissue Inhibitor of Metalloproteinases; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D004338:Drug Combinations; D006023:Glycoproteins; D007797:Laminin; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D011506:Proteins; D011509:Proteoglycans; D019714:Tissue Inhibitor of Metalloproteinases; C059485:matrigel; D019716:Tissue Inhibitor of Metalloproteinase-2; D003094:Collagen; D017364:Collagenases; D018093:Gelatinases; D008666:Metalloendopeptidases; D019278:Matrix Metalloproteinase 3; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1